<unk>  is a plasma kallikrein inhibitor (monoclonal antibody) that is FDA approved for the prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.   Common adverse reactions include injection site reactions, upper respiratory infections, headache, rash, myalgia, dizziness, and diarrhea.
Lanadelumab
Ustekinumab
Alirocumab
Nebacumab
Evolocumab
Burosumab
Durvalumab
Raxibacumab